{"schema_version":"secwatch.filing_event.v1","accession":"0000886744-26-000003","form_type":"8-K","ticker":"GERN","cik":"0000886744","company_name":"GERON CORP","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.925263+00:00","generated_at":"2026-05-16T11:00:12.042971+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Geron guides 2026 RYTELO revenue $220-240M; OPEX $230-240M","bullets":["2026 RYTELO net product revenue expected $220-240M.","2026 total operating expenses expected $230-240M.","Amended Pharmakon term loan: Tranche B ($75M) and Tranche C ($50M) draw deadlines extended to July 30, 2026.","Implemented strategic restructuring to streamline operations and support RYTELO commercial growth.","Presented new IMerge trial analyses at ASH 2025 reinforcing RYTELO differentiation in LR-MDS."],"urls":{"canonical":"https://secwatch.observer/filing/0000886744-26-000003","json":"https://secwatch.observer/filing/0000886744-26-000003.json","markdown":"https://secwatch.observer/filing/0000886744-26-000003.md","text":"https://secwatch.observer/filing/0000886744-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886744/000088674426000003/0000886744-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886744/000088674426000003/gern-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:00:12.042971+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}